A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder"
Clinical Trial Grant
Administered By
Psychiatry & Behavioral Sciences
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
June 23, 2017
End Date
June 12, 2020
Administered By
Psychiatry & Behavioral Sciences
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
June 23, 2017
End Date
June 12, 2020